Pharmacovigilance – News and Features

Novosom AG today announced that it has acquired an exclusive, worldwide license from Isis Pharmaceuticals to access certain antisense inhibitors targeting CD40 mRNA for a number of indications.

Amgen to launch Nplate™ NEXUS program to provide treatment access and patient support programs.

This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an alkaline phosphatse.

Biota has announced the commencement of dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of HRV.

The trial is being carried out by the Mayo Phase 2 Consortium using systemic administration of Oncolytics' formulation of the human reovirus.

Scientists have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off.

Cancer biologists are turning their attention to learn how tumor growth might be stopped at the earliest opportunity.

Biota Holdings has commenced the dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus.

Researchers find that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer.

The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.